# New Insights in Alzheimer’s Treatment Breakthroughs

Newsy: Alzheimer’s News Weekly
Published: 2026-04-06T13:30:00.270Z
Source: https://newsyai.com/edition/2d2de3b9-7213-40db-a9ed-13cb66ee5701
Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md

---

# Alzheimer’s Treatment Briefing
**Coverage period: March 31–April 6, 2026**

Below are this week’s most meaningful, truly **new** developments, ranked by impact on treatment and access.[[1]](https://www.alzforum.org/news/conference-coverage/lewy-bodies-blunt-amyloid-immunotherapy-trial-measure-how-much)[[2]](https://www.alzforum.org/news/conference-coverage/adding-emtbr-tau243-p-tau217-sharpens-ad-diagnosis)

**1. Lewy body clumps weaken plaque-clearing drugs; new test-trial combo on the way**  
- **Overview**  
  Scientists analyzed past big trials of plaque-removing shots like gantenerumab and found that when brains also have Lewy body clumps (built from a different sticky protein called alpha-synuclein, seen in 40-55% of Alzheimer’s cases), the drugs barely slow thinking decline—dropping benefits by 5-11%. Pure Alzheimer’s cases got a 12% slowdown. Eli Lilly starts a Phase 2 trial testing their plaque shot donanemab in 350 people confirmed positive for both plaques and Lewy signs via blood tests.[[1]](https://www.alzforum.org/news/conference-coverage/lewy-bodies-blunt-amyloid-immunotherapy-trial-measure-how-much)  
- **Why this matters**  
  Like fighting a fire only to find termites eating the house too, this explains why plaque cleaners help modestly at best—co-clumps speed decline. Spotting them early via blood lets doctors pick best patients or add termite-targeting helpers, boosting real-world wins.

**2. Two blood markers team up to nail Alzheimer’s diagnosis, slashing wrong calls**  
- **Overview**  
  Adding a tau fragment marker (eMTBR-tau243) to the star blood check (p-tau217 percentage) cuts false alarms for confirmed Alzheimer’s from 43% to just 16%, while spotting true cases jumps to 84%. It predicts faster tangle spread and memory drops better than solo tests.[[2]](https://www.alzforum.org/news/conference-coverage/adding-emtbr-tau243-p-tau217-sharpens-ad-diagnosis)  
- **Why this matters**  
  Think of it as a double-check lock versus a single shaky one—fewer mix-ups mean quicker starts on plaque removers for the right folks, speeding trials and care without wasting time or side effects on non-Alzheimer’s issues.

**3. Anti-tangle shot posdinemab drops key marker but misses slowing symptoms**  
- **Overview**  
  Full AD/PD data on Janssen’s posdinemab (Phase 2b) showed it slashed blood p-tau217 (a tangle warning sign) sharply, yet daily thinking and function kept declining at full speed in early Alzheimer’s patients—no slowdown seen.[[3]](https://www.alzforum.org/news/conference-coverage/posdinemab-epitaph-p-tau217-tanked-dementia-marched)  
- **Why this matters**  
  Clearing road signs doesn't fix potholes; it flags that some tangle targets hit biology but not daily life. Shifts focus to combo attacks or better tangle hitters, avoiding dead ends while building smarter next tries.

**4. Repurposed brain signal booster NSC001 enters Phase 2 for mild-moderate cases**  
- **Overview**  
  An upgraded old drug (NGX267, now NSC001) that wakes key brain messengers (M1 type) starts Phase 2 in 90 Europeans with mild-moderate Alzheimer’s. Safe in healthy folks, tests low doses with/without a side-effect blocker; tracks thinking, brain waves, and marks through 2027.[[4]](https://www.alzforum.org/news/conference-coverage/old-cholinergic-drug-gets-new-chance-phase-2)  
- **Why this matters**  
  Like rebooting fuzzy radio signals for clearer chat, it revives basics ignored by plaque focus—cheap pill potential fills gaps for later stages, pairing with new shots for fuller coverage.

**5. Xanamem trial extension doses first patient, eyeing full data by November**  
- **Overview**  
  Actinogen gave the first open-label dose in the XanaMIA Phase 2b/3 extension after 36 weeks randomized; daily 10mg pill for Alzheimer’s, building long-term safety/effect data toward late 2026 readout.[[5]](https://www.clinicaltrialsarena.com/news/actinogen-first-patient-xanamia-trial)  
- **Why this matters**  
  Extensions like bonus seasons test staying power; steady progress on oral options means more non-shot choices soon, easing access for ongoing care beyond plaque cleaners.

## What this means for care right now
- **Screen for co-clumps**: Ask for alpha-synuclein blood tests before plaque shots to max benefits—watch Lilly’s donanemab trial.[[1]](https://www.alzforum.org/news/conference-coverage/lewy-bodies-blunt-amyloid-immunotherapy-trial-measure-how-much)  
- **Supercharge blood tests**: Push %p-tau217 + eMTBR-tau243 combos for spot-on starts, cutting delays.[[2]](https://www.alzforum.org/news/conference-coverage/adding-emtbr-tau243-p-tau217-sharpens-ad-diagnosis)  
- **Mix it up**: Tau flops highlight need for pairs (plaque + signals/boosters); track NSC001, Xanamem.[[4]](https://www.alzforum.org/news/conference-coverage/old-cholinergic-drug-gets-new-chance-phase-2)[[5]](https://www.clinicaltrialsarena.com/news/actinogen-first-patient-xanamia-trial)  
- **Precision first**: These refine who/when for today’s tools, paving multi-angle futures.

## Sources
- Lewy bodies & donanemab trial (April 3, 2026), [Alzforum](https://www.alzforum.org/news/conference-coverage/lewy-bodies-blunt-amyloid-immunotherapy-trial-measure-how-much)[[1]](https://www.alzforum.org/news/conference-coverage/lewy-bodies-blunt-amyloid-immunotherapy-trial-measure-how-much)  
- Blood marker combo (April 1, 2026), [Alzforum](https://www.alzforum.org/news/conference-coverage/adding-emtbr-tau243-p-tau217-sharpens-ad-diagnosis)[[2]](https://www.alzforum.org/news/conference-coverage/adding-emtbr-tau243-p-tau217-sharpens-ad-diagnosis)  
- Posdinemab details (April ~2, 2026), [Alzforum](https://www.alzforum.org/news/conference-coverage/posdinemab-epitaph-p-tau217-tanked-dementia-marched)[[3]](https://www.alzforum.org/news/conference-coverage/posdinemab-epitaph-p-tau217-tanked-dementia-marched)  
- NSC001 Phase 2 (April 2, 2026), [Alzforum](https://www.alzforum.org/news/conference-coverage/old-cholinergic-drug-gets-new-chance-phase-2)[[4]](https://www.alzforum.org/news/conference-coverage/old-cholinergic-drug-gets-new-chance-phase-2)  
- Xanamem OLE first patient (April 2, 2026), [Clinical Trials Arena](https://www.clinicaltrialsarena.com/news/actinogen-first-patient-xanamia-trial)[[5]](https://www.clinicaltrialsarena.com/news/actinogen-first-patient-xanamia-trial)  

Quiet week on blockbusters, but diagnosis/trial tweaks sharpen the path ahead.
